Form D · Biotechnology
Kindred Biosciences, Inc.
Burlingame, CA · CIK 0001561743
Offering snapshot reported Sep 20, 2013 · SEC filing
- Reported sold
- $5.31M Offering amount: $5.31M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 31, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 20, 2013 | Initial | $5,309,755 | No comparison | 18 | SEC filing |
| Sep 13, 2013 | Amendment | $5,896,848 | $3,346,324vs Jul 12, 2013 | 50 | SEC filing |
| Jul 12, 2013 | Initial | $2,550,524 | No comparison | 18 | SEC filing |
| Nov 19, 2012 | Initial | $1,000,000 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $78K
- Form D file number
- 021-203323
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| SDDCO Brokerage Advisors | 153563 |
Source: Form D, filed Sep 20, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Denise Bevers | Executive |
| Richard Chin | Director, Executive |
| Ernest Mario | Director |
| Stephen Sundlof | Executive |
| Ervin Vezspremi | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1499 Bayshore Hwy. #226
Burlingame, CA, 94010
Burlingame, CA, 94010